Liquidia Technologies

Developed out of the University of North Carolina at Chapel Hill and located right around the corner from our office, Liquidia has developed a proprietary PRINT (Pattern Replication In Non-wetting Templates) technology platform, a system for precision molding of nano- and microparticles that allows for the delivery of biological and small molecule vaccines and therapeutics. The company’s technology makes it possible to design vaccines and therapies with precise control of particle size, shape and composition. In 2011, the Gates Foundation made its first-ever biotech equity investment in Liquidia, recognizing its potential in the field of vaccine development.

The PRINT platform allows Liquidia to create precisely engineered vaccines, therapeutics and other health-related products.

Liquidia Technologies

Research Triangle Park, NC

Website

07.25.2018
Liquidia Technologies Announces Pricing of Initial Public Offerin…

Read More

01.03.2018
Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients w…

Read More